A randomized, double-blind, placebo-controlled, Phase 1/2a trial protocol to assess the safety and efficacy of TAK-101 administered by microneedles in patients with celiac disease. Principles and Practice of Clinical Research, [S. l.], v. 8, n. 3, p. 37–48, 2022. DOI: 10.21801/ppcrj.2022.83.5. Disponível em: https://journal.ppcr.org/index.php/ppcrjournal/article/view/185.. Acesso em: 14 apr. 2025.